Skip to main content
Howard Hughes Medical Institute Author Manuscripts logoLink to Howard Hughes Medical Institute Author Manuscripts
. Author manuscript; available in PMC: 2009 Apr 2.
Published in final edited form as: Bioorg Med Chem. 2008 Mar 27;16(10):5754–5760. doi: 10.1016/j.bmc.2008.03.061

Synthesis and biochemical application of 2′-O-methyl-3′-thioguanosine as a probe to explore group I intron catalysis

Jun Lu 1, Nan-Sheng Li 1, Raghuvir Sengupta 1, Joseph A Piccirilli 1,*
PMCID: PMC2664738  NIHMSID: NIHMS53498  PMID: 18397828

Abstract

Oligonucleotides containing 3′-S-phosphorothiolate linkages provide valuable analogues for exploring the catalytic mechanisms of enzymes and ribozymes, both to identify catalytic metal ions and to probe hydrogen-bonding interactions. Here we have synthesized 2′-O-methyl-3′-thioguanosine to test a possible hydrogen bonding interaction in the Tetrahymena ribozyme reaction. We developed an efficient method for the synthesis of 2′-O-methyl-3′-thioguanosine phosphoramidite in eight steps starting from 2′-O-methyl-N2-(isobutyryl) guanosine with 10.4% overall yield. Following incorporation into oligonucleotides using solid phase synthesis, we used this new analogue to investigate whether the 3′-oxygen of the guanosine cofactor in the Tetrahymena ribozyme reaction serves as an acceptor for the hydrogen bond donated by the adjacent 2′-hydroxyl group. We show that regardless of whether the guanosine cofactor bears a 3′-oxygen or 3′-sulfur leaving group, replacing the adjacent 2′-hydroxyl group with a 2′-methoxy group incurs the same energetic penalty, providing evidence against an interaction. These results indicate that the hydrogen bond donated by the guanosine 2′-hydroxyl group contributes to catalytic function in a manner distinct from the U-1 2′-hydroxyl group.

Keywords: Group I intron, RNA catalysis, thionucleosides, atomic mutation cycle, 3′-S-phosphorothioamidite

1. Introduction

Oligonucleotides containing 3′-S-phosphorothiolate linkages (Figure 1), in which a sulfur atom replaces the 3′-bridging oxygen atom of the phosphodiester linkage, provide valuable analogues for studying RNA structure and function.1-14 Oligodeoxynucleotides containing this linkage have been used to investigate the resolution of the Holliday junction by RuvC, DNA repair by E. coli DNA T:G mismatch endonuclease, and the nucleolytic activity of E. coli DNA polymerase I and the restriction endonuclease EcoRV.1,4,9-11,14,15 Phosphorothiolate linkages have also yielded fundamental insights into the catalytic mechanisms of RNA enzymes and RNA splicing machineries, revealing the participation of metal ions and hydrogen bonds in their catalytic function.2,3,5,7,8,16-21 With respect to the self-splicing group I intron, which has served as a model system for studying the chemistry of RNA splicing and the principles of phosphoryl transfer reactions, crystallographic and biochemical analyses, including studies that utilize phosphorothiolates, have revealed a complex network of interactions within the active site of this ribozyme (Figure 2).22-24 Developing new methods to identify and characterize these interaction networks remains imperative to understanding catalysis by this and other RNAs.

Figure 1. A 3′-S-phosphorothiolate linkage.

Figure 1

Figure 2. Transition state model of phosphoryl transfer catalyzed by the Tetrahymena group I ribozyme.

Figure 2

MA, MB, and MC represent the catalytic metal ions in the active site. The red rectangle highlights the 2′-hydroxyl group of the guanosine nucleophile under investigation. Hatched lines indicate putative hydrogen bonds, and dots symbolize metal ion coordination. Figure taken by permission from reference 21(b).

We previously devised an atomic mutation cycle (AMC) to determine whether a RNA 2′-hydroxyl group donates a functionally important hydrogen bond (Figure 3).25-27 AMC analysis requires the construction of three analogues bearing modifications at the 2′-position: -OCH3, -NH2, and -NHCH3. When the energetic penalty for the 2′-OH to 2′-OCH3 substitution (ΔΔGOH → OCH3) exceeds that for the 2′-NH2 to 2′-NHCH3 substitution (ΔΔGNH2→NHCH3), we attribute the difference to the absence of the hydrogen atom (ΔGH removal) from the 2′-OCH3 analogue. When the absence of the hydrogen atom engenders an energetic penalty (ΔGH removal > 0), we infer that the 2′-hydroxyl group donates a hydrogen bond. We have used this strategy with success to investigate the 2′-hydroxyl groups along the reaction coordinate in the Tetrahymena ribozyme reaction. The cleavage site uridine (U-1) and the guanosine nucleophile 2′-hydroxyl groups appear to donate hydrogen bonds in the transition state of the reaction, yielding ΔGH removal values of 2.5 and 3.5 kcal/mol, respectively.27

Figure 3. Atomic mutation cycle analysis of an RNA 2′-hydroxyl group.

Figure 3

As the U-1 2′-hydroxyl group donates a hydrogen bond to the adjacent 3′-oxygen atom in the transition state of the ribozyme reaction (Figure 2), we wanted to test whether the analogous interaction involving the guanosine 2′-hydroxyl group also occurs.28 AMC analysis also offers a strategy to identify the corresponding hydrogen bond acceptor. Mutations that disrupt a hydrogen bond interaction between the 2′-hydroxyl group and a potential acceptor should attenuate the cost of methoxy substitution (ΔΔGNH2 → NHCH3) and therefore decrease the value of ΔGH removal, as the ribozyme bearing the natural nucleotide no longer gains a catalytic advantage from hydrogen bond donation by the 2′-hydroxyl group.27 To test whether the guanosine nucleophile 2′-hydroxyl group donates a hydrogen bond to the adjacent 3′-oxygen during the reaction, we plan to perform AMC analysis in the context of a 3′-sulfur atom. Sulfur is a weak hydrogen bond acceptor compared to oxygen.28-33 Therefore, if the guanosine 2′-hydroxyl group donates a hydrogen bond to the 3′-oxygen during the reaction, ΔΔGOH → OCH3 and ΔGH removal should decrease in a 3′-sulfur background. To conduct AMC analysis, the four 3′-thioguanosine analogues corresponding to those in Figure 3 must be prepared. As a starting point for this analysis, here we describe the synthesis of one of these analogues and its corresponding phosphoramidite, 2′-methoxy-3′-thioguanosine.* Following solid-phase oligonucleotide synthesis, we measured the reactivity of this analogue in the Tetrahymena ribozyme reaction and found that the energetic cost of methoxy substitution (ΔΔGOH → OCH3) remains the same regardless of the identity of 3′-atom (oxygen/sulfur). These results provide evidence against a hydrogen bond interaction between the 2′-hydroxyl group and the 3′-oxygen atom of the guanosine nucleophile.

2. Results and Discussion

2.1 Synthesis of 2′-O-methyl-3′-thioguanosine phosphoramidite

In 1999, Matulic-Adamic reported the synthesis of 3′-thioguanosine and its 3′-phosphorothioamidite starting from guanosine.34 Reaction of 5′-N2-protected guanosine with 2-acetoxyisobutyryl bromide afforded the 3′-β-bromo-derivative stereoselectively, which was converted to 3′-S-acyl ribofuranosyl intermediates. The S-acylated nucleosides were then converted in seven steps to the 3′-S-phosphorothioamidite in 13% overall yield from guanosine. The corresponding 2′-O-methyl-3′-thioguanosine phosphoramidite has not been reported. We adapted Matulic-Adamic's synthetic route to the synthesis of 2′-O-methyl-3′-thioguanosine phosphoramidite 10.

Our synthesis begins with the commercially available 2′-O-methyl-N2-isobutyrylguanosine 1 (Scheme 1). Reaction of 1 with (tert-butyl)chlorodiphenylsilyl (t-BuPh2SiCl) gave the corresponding 5′-silyl derivative 2 in 90% yield. In the presence of 4-(dimethylamino)pyridine (DMAP), treatment of compound 2 with trifluoromethanesulfonyl chloride in CH2Cl2 at 0 °C gave the 3′-triflate derivative 3 in 83% yield.35 Subsequent SN2 substitution with NaBr in acetone afforded the desired 3′-bromo derivative 4 in 58% yield. Treatment of 4 with KSAc in DMF at 60 °C yielded a mixture of the desired 3′-S-acetyl derivative 6 and the 3′,4′-unsaturated derivative 5, which forms via a competing elimination reaction.34 According to the 1H NMR spectra, 6 and 5 form in a 9:5 ratio. These two compounds could not be separated by silica gel chromatography. We treated the mixture of 5 and 6 with Bu4NF·3H2O and AcOH in THF and subsequently isolated the desired 5′-deprotected derivative 7 in 28% yield (two steps).During the deprotection, the 3′,4′-unsaturated derivative decomposed and therefore could not be isolated. Protection of 7 as the 5′-O-dimethoxytrityl ether was performed in dry pyridine for 24 hours by using excess 4,4′-dimethoxytritylchloride (DMTrCl, 3 equivalents), giving the 5′-DMTr protected compound 8 in 96% yield.

Scheme 1.

Scheme 1

Reagents and conditions: i) tBuPh2SiCl, Py, rt, 20 h. ii) CF3SO2Cl, DMAP, CH2Cl2 0 □ 2 h. iii) NaBr, CH3COCH3, reflux, 3 h. iv) KSAc, DMF, 60 °C, 24 h. v) Bu4NF·3H2O, AcOH, THF, rt, 36 h. vi) (MeO)2TrCl, Py, rt, 24 h. vii) Guanidine hydrochloride-NaOMe (4:1), MeOH-CH2Cl2 (1:1), rt, 30 min. viii) (i-Pr)2 NP(Cl)OC2H4CN, i-Pr2NEt, 1-methyl-1H-imidazole, rt, 1 h

To prepare the 3′-phosphorothioamidite 10, the selective removal of the 3′-S-acetyl group of compound 8 must occur without the loss of the N2-isobutyryl group. A solution of NaOMe and guanidine hydrochloride in methanol proved to be effective.36 Treatment of 8 with a 4:1 mixture of guanidine hydrochloride and 25% NaOMe in methanol produced the 3′-SH derivative 9 in 85% yield. Phosphitylation of compound 9 under standard conditions gave quantitative conversion to the 3′-phosphorothioamidite 10. We subsequently incorporated the 2′-O-methyl-3′-thioguanosine phosphoramidite into the oligonucleotide sequence, CUCG3′S,2′OCH3A, as previously described.43 Based on trityl yield data, coupling efficiencies throughout oligonucleotide synthesis were excellent (data not shown).

2.2 Tetrahymena ribozyme reactions with substrates bearing guanosine (G2′OH), 2′-O-methylguanosine (G2′OCH3), 3′-thioguanosine (G3′S,2′OH), and 2′-O-methyl-3′-thioguanosine(G3′S,2′OCH3)

Following oligonucleotide synthesis and deprotection, we determined the effect of the 3′-sulfur atom on 2′-methoxy substitution in the Tetrahymena ribozyme reaction. We utilized a reaction that mimics the second step of group I intron self-splicing in which an oligonucleotide product (CCCUCU) cleaves a specific phosphodiester bond of CUCGA, a 3′-splice site analogue (equation 1).37-41

CCCUCU+CUCGpACECCUCUpA+CUCG (1)

We measured the rates of cleavage for CUCG2′OHA and CUCG2′OCH3A to obtain the cost of 2′-methoxy substitution in the context of a 3′-oxygen atom. Under conditions where chemistry is rate-limiting, 2′-methoxy substitution has a 6.9 kcal/mol (8.8 × 104-fold) effect on reactivity (ΔΔGOH→OCH3) (Figure 4). This effect remains similar in the context of the 3′-sulfur atom: under the same conditions CUCG3′S,2′OCH3A reacts 3.1 × 104-fold slower than does CUCG3′S,2′OHA, indicating that replacement of the 2′-OH group with a 2′-OCH3 group imposes a 6.2 kcal/mol effect on reactivity (ΔΔGOH→OCH3) (Figure 4). If the 2′-hydroxyl group were donating a hydrogen bond to the adjacent 3′-oxygen sulfur substitution at the 3′-position would be expected to disrupt this interaction and therefore diminish the catalytic advantage of the 2′-OH group over the 2′-OCH3 group. However, as sulfur substitution only has a ~3-fold (~0.7 kcal/mol) effect on ΔΔGOH→OCH3, our results provide evidence against this interaction, suggesting that another neighboring group must accept the hydrogen bond from the 2′-hydroxyl group.

Figure 4. Ribozyme reactions with CUCG2′OHA, CUCG2′OCH3A, CUCG3′S,2′OHA and CUCG3′S,2′OCH3A.

Figure 4

Reactions took place in the presence of saturating ribozyme and product to form the E•P complex. CUCGXA substrates were 5′-32P-labeled (denoted by the asterisk). For ribozyme reactions with the phosphorothiolate substrates, we observed that CUCG3′SH,2′OCH3 migrated slower than CUCG3′SH,2′OH. To confirm the presence of the free thiol, we treated the ribozyme-catalyzed products with iodoacetamide, an alkylating sulfhydryl reagent (data not shown). Both CUCG3′SH,2′OH and CUCG3′SH,2′OCH3 were susceptible to iodoacetamide modification and, upon alkylation, comigrated (data not shown).

3. Conclusions

We established an efficient method for the synthesis of 2′-O-methyl-3′-thioguanosine phosphoramidite 10 in 10.4% overall yield starting from 2′-O-methyl-N2-isobutyrylguanosine. Using solid-phase methods, we achieved efficient incorporation of the 2′-O-methyl-3′-thioguanosine phosphoramidite into RNA. We have also utilized this analogue to investigate a potential hydrogen bond interaction in the Tetrahymena ribozyme reaction. Our results provide evidence against a model in which the guanosine 3′-oxygen accepts a hydrogen bond from the adjacent 2′-hydroxyl group. Thus, the hydrogen bond donated by the guanosine 2′-hydroxyl group contributes to catalytic function in a manner distinct from the U-1 2′-hydroxyl group. Further analysis will be required to identify its hydrogen bonding partner.

4. Experimental

4.1. Chemistry

All reactions were carried out under a positive pressure of Ar in anhydrous solvents. Commercially available reagents and anhydrous solvents were used without further purification. 1H, 13C, and 31P NMR spectra were recorded on a Bruker 500 or Bruker 400 MHz NMR spectrometer. 1H chemical shifts are reported in δ (ppm) relative to tetramethylsilane and 13C chemical shifts δ (ppm) relative to the solvent used. High resolution mass spectra were obtained from the Department of Chemistry, University of California at Riverside, on the VG-ZAB instrument.

4.1.1. 5′-O-(tert-Butyl)diphenylsilyl-2′-O-methyl-N2-isobutyrylguanosine (2)

To a stirred solution of 2′-O-methyl-N2-isobutyrylguanosine 1 (2.02 g, 5.49 mmol) in pyridine (20 mL), (tert-butyl)diphenylsilyl chloride (2.25 mL, 8.23 mmol) was added under Ar. The mixture was stirred at room temperature for 20 h, then quenched with MeOH (4 mL), and evaporated to a syrup. The residue was dissolved in CHCl3 (40 mL) and washed with H2O. The organic layer was dried over anhydrous sodium sulfate. The sodium sulfate was filtered off, and the solvent was removed by evaporation under vacuum. The residue was purified by silica gel chromatography, eluting with 2% methanol in chloroform, to give the product as a white foam: 2.99 g (90% yield). 1H NMR (CDCl3): δ 12.16 (s, 1H), 9.10 (s, 1H), 7.97 (s, 1H), 7.65-7.33 (m, 10H), 5.94 (d, 1H, J = 5.0 Hz), 4.57 (t, 1H, J = 5.0 Hz), 4.17(t, 1H, J = 5.0 Hz), 4.13 (m, 1H), 3.98 (dd, 1H, J = 2.5, 11.5 Hz), 3.85 (dd, 1H, J = 3.5, 11.5 Hz), 3.43 (s, 3 H), 2.67 (m, 1H), 1.22 (d, 6H, J = 6.5 Hz), 1.06 (s, 9H). 13C NMR (CDCl3): δ 178.9, 155.5, 148.1, 147.8, 137.1, 135.6, 135.4, 132.6, 132.4, 130.0, 129.9, 127.9, 127.8, 121.4, 85.7, 85.1, 84.1, 69.3, 63.5, 58.8, 36.3, 26.9, 19.2, 19.0, 18.9. HRMS (FAB+): m/z calc for C31H40N5O6Si [M+H+]: 606.2748; found: 606.2760.

4.1.2. 5′-O-(tert-Butyl)diphenylsilyl-2′-O-methyl-3'-O-trifluorosulfonyl-N2-isobutyryl guanosine (3)

To a solution of 2 (606 mg, 1.0 mmol) and DMAP (244 mg, 2 mmol) in dry MeCN (6 mL), CF3SO2Cl (0.16 mL, 1.5 mmol) was added at 0 °C under Ar. After the mixture was stirred at 0 °C for 2 h, the reaction was quenched with ice water (5 mL) and the mixture was stirred for 15 min. The reaction mixture was diluted with CH2Cl2 (20 mL). The organic layer was separated, and the aqueous layer was extracted with CH2Cl2 (2×30 mL). The organic layers were combined and washed with H2O and brine and subsequently dried over anhydrous sodium sulfate. The sodium sulfate was filtered off, and the solvent was removed by evaporation under vacuum. The residue was purified by silica gel chromatography, eluting with 2% methanol in chloroform, to give the product as a white foam: 644 mg (87% yield). 1H NMR (CDCl3): δ 12.02 (s, 1H), 8.38 (s, 1H), 7.83 (s, 1H), 7.63-7.36 (m, 10H), 5.90 (d, 1H, J = 6.5 Hz), 5.75 (t, 1H, J = 4.0 Hz), 4.59 (t, 1H, J = 5.5 Hz), 4.38 (m, 1H), 3.96 (dd, 1H, J = 3.0, 12.0 Hz), 3.84 (dd, 1H, J = 3.0, 12.0 Hz), 3.42 (s, 3H), 2.54 (m, 1H), 1.24 (d, 6H, J = 6.5 Hz), 1.04 (s, 9H). 13C NMR (CDCl3): δ 178.3, 155.2, 148.1, 147.7, 137.0, 135.4, 135.3, 131.9, 131.8, 130.3, 130.2, 128.0, 121.7, 84.9, 83.2, 81.9, 81.3, 77.3, 77.0, 62.3, 59.4, 36.5, 26.7, 19.1, 18.9, 18.8. HRMS (FAB+): m/z calc for C32H39N5O8F3SiS, [M+H+]: 738.2210; found: 738.2235.

4.1.3. 5′-O-(tert-Butyl)diphenylsilyl-2′-O-methyl-3′-β-bromo-N2-isobutyryl-guanosine (4)

A mixture of 3 (1.56 g, 2.12 mmol) and NaBr (0.87 g, 8.47 mmol) in acetone (20 mL) was heated under reflux for 3 h under Ar. The solvent was removed under reduced pressure, and the residue was purified by silica gel chromatography, eluting with 1-3% methanol in chloroform, to give the product as a white foam: 0.822 g (58% yield). 1H NMR (CDCl3):δ12.14 (s, 1H), 8.95 (s, 1 H), 7.97 (s, 1H), 7.70-7.37 (m, 10H), 5.84 (d, 1H, J = 1.5 Hz), 4.41 (d, 1H, J = 3.5 Hz), 4.36(m, 2H), 4.02 (dd, 1H, J = 5.5, 10.5 Hz), 3.96 (dd, 1H, J = 6.0, 10.5 Hz), 3.47 (s, 3H), 2.66 (m, 1H), 1.23 (d, 6H, J = 5.5 Hz), 1.07 (s, 9H). 13C NMR (CDCl3):δ178.6, 155.6, 147.8, 147.7, 137.3, 135.5, 135.4, 132.8, 132.7, 130.0, 129.9, 127.8, 127.7, 121.2, 92.2, 88.8, 81.3, 64.5, 58.4, 50.2, 36.4, 26.8, 19.2, 19.0, 18.9. HRMS (FAB+): m/z calc for C31H39N5O5F3SiBr [M+H+]: 668.1898; found: 668.1913.

4.1.4 5′-O-(tert-butyl)diphenylsilyl-2′-O-methyl-3′-deoxy-β-D-glycero-pent-3′-enofuranosyl-N-2-isobutyrylguanosine (5) and 5′-O-(tert-Butyl) diphenyl-silyl-2′-O-methyl-3′-S-acetyl-N2-isobutyrylguanosine (6)

To a solution of 4 (49 mg, 0.073 mmol) in dry DMF (2 mL), potassium thioacetate (25 mg, 0.22 mmol) was added, and the mixture was stirred at 60 °C for 24 h and evaporated to a syrup. The residue was partitioned between an aqueous NaHCO3 solution/brine (v/v, 1:1) and CH2Cl2; the organic layer was dried (Na2SO4) and evaporated. The residue was purified by silica gel chromatography; eluting with 1-2% methanol in chloroform, to give a mixture of 5 and 6 (35 mg) (5/6 5:9 based on 1H NMR). 1H NMR (CDCl3):δ12.08 (s, 1H, 5), 11.91 (s, 1H, 6), 9.24 (s, 1H, 6), 8.71 (s, 1H, 5), 7.99 (s, 1H, 5), 7.86 (s, 1H, 6), 7.28-7.70 (m, 20 H, 5 + 6), 6.29 (d, 1H, J = 1.6 Hz, 5), 5.89 (s, 1 H, 6), 5.63 (m, 1H, 6), 5.43 (t, 1H, J = 1.1 Hz, 5), 4.66 (s, 1 H, 5), 4.43 (d, 1H, J = 4.7 Hz, 6), 4.29 (d, 1H, J = 9.0 Hz, 6), 4.13 (m, 1H, 5), 3.86 (dd, 1 H, J = 2.1, 11.9 Hz, 6), 3.71 (dd, 1 H, J = 3.5, 11.9 Hz, 6), 3.50 (s, 3H, 6), 3.34 (s, 3H, 5), 2.67 (m, 1 H, 5), 2.61 (m, 1 H, 6), 2.44 (s, 3H, 6), 1.21-1.27 (m, 12 H, 5 + 6), 1.07 (s, 9H, 5), 0.88 (s, 9H, 6).

4.1.5. 3′-S-Acetyl-2′-O-methyl-N2-isobutyryl-3′-thioguanosine (7)

To the above mixture 5/6 (0.90 g) in THF (15 mL), AcOH (0.40 mL, 6.5 mmol) was added, followed by Bu4NF·3H2O (0.80 g, 2.6 mmol). The mixture was stirred at room temperature for 24 h, then diluted with CH2Cl2, and washed with H2O and 10% aq. NaHCO3. The aqueous layers were extracted with CH2Cl2 and the combined organic layers were dried (Na2SO4). Following removal of the solvent by evaporation under vacuum, the resulting residue was purified by silica gel chromatography, eluting with 2-4% methanol in chloroform, to give product 7 as a yellow foam: (137 mg, 28% from 4). 1H NMR:δ12.04 (s, 1H), 9.31 (s, 1H), 7.97 (s, 1H), 5.86 (d, 1H, J = 2.0 Hz), 5.06 (dd, 1H, J = 5.5, 9.0 Hz,), 4.31 (d, 1H, J = 5.5 Hz), 4.21 (d, 1H, J = 9.0 Hz,), 3.97 (d, 1H, J = 13.0 Hz), 3.72 (d, 1H, J = 13.0 Hz,), 3.46 (s, 3H), 2.74 (m, 1H), 2.44 (s, 3H), 1.28 (d, 6H, J = 7.0 Hz). 13C NMR (CDCl3):δ 196.2, 179.6, 155.4, 147.8, 147.3, 138.4, 121.2, 88.2, 85.1, 85.0, 60.8, 58.7, 43.4, 36.1, 30.6, 19.0, 18.8. HRMS (FAB+): m/z calc for C17H24N5O6S+ [M+H+]: 426.1447; found: 426.1430.

4.1.6 5′-O-(4,4′-Dimethoxytrityl)-3′-S-acetyl-2′-O-Methyl-N2-isobutyryl-3′-thio-guanosine (8)

To a solution of 7 (48 mg, 0.11 mmol) in dry pyridine (2 mL), DMTrCl (115 mg, 0.34 mmol) was added. The mixture was stirred at room temperature for 20 h, quenched with MeOH, and evaporated to a syrup which was partitioned between 5% aq. NaHCO3 and CH2Cl2. The organic layer was washed with brine, dried (Na2SO4), and evaporated, and the residue was purified by chromatography (silica gel, gradient 0-2% MeOH/CH2Cl2 with 0.5% Et3N to give compound 8 (79 mg, 96% yield). 1H NMR: δ7.88 (s, 1H), 7.15-7.31 (m, 9 H), 6.71-6.73 (m, 4 H), 5.90 (s, 1H), 5.58 (m, 1H), 4.36 (d, 1 H, J = 5.0 Hz), 4.17 (dd, 1H, J = 3.0, 11.0 Hz), 3.76 (s, 6H), 3.47 (s, 3 H), 3.45 (m, 1 H), 3.15 (m, 1H), 2.55 (m, 1H), 2.35 (s, 3H), 1.18 (d, 3 H, J = 7.0 Hz), 1.12 (d, 3 H, J = 7.0 Hz). 13C NMR (CDCl3): δ195.9, 178.7, 158.3, 155.6, 147.4, 147.3, 144.3, 138.7, 135.6, 135.5, 129.9, 128.0, 127.6, 126.7, 121.9, 112.82, 112.80. HRMS (FAB+): m/z calc for C38H41N5O8NaS [M+Na+]: 750.2568; found: 750.2594.

4.1.7. 5′-O-(4,4′-Dimethoxytrityl)-2′-O-methyl-N2-isobutyryl-3′-thioguanosine (9)

To a mixture of guanidine hydrochloride (208 mg, 0.285 mmol), MeOH (5 mL) and NaOCH3 (25% in MeOH, 60 μL) was added a solution of 8 (20 mg, 0.027 mmol) in CH2Cl2 (5 mL), and the mixture was stirred at room temperature for 30 min. The reaction mixture was partitioned between H2O and CH2Cl2. The organic layer was dried over anhydrous sodium sulfate. The sodium sulfate was filtered off, and the solvent was removed by evaporation under vacuum. The residue was purified by silica gel chromatography, eluting with 2% methanol in chloroform with 0.5% Et3N, to give compound 9 (16 mg, 85%). 1H NMR (CDCl3): δ12.26 (s, 1H), 9.59 (s, 1H), 8.04 (s, 1H), 7.17-7.42 (m, 9H), 6.72-6.81 (m, 4H), 5.96 (d, 1H, J = 1.2 Hz), 4.04 (d, 1H, J = 9.5 Hz), 4.00 (d, 1H, J = 4.5 Hz), 3.75 (s, 6H), 3.67 (m, 1H), 3.60 (d, 1H, J = 11.0 Hz), 3.48 (s, 3H), 3.38 (m, 1H), 2.58 (m, 1H), 1.71 (d, 1H, J = 10.0 Hz), 1.13 (d, 6H, J = 5.5 Hz). 13C NMR (CDCl3): δ179.3, 158.6, 155.7, 147.9, 147.6, 144.3, 137.0, 135.5, 135.4, 130.0, 129.9, 128.0, 127.9, 127.0, 121.6, 113.2, 87.2, 86.5, 86.2, 85.5, 61.0, 58.7, 55.2, 39.0, 36.1, 18.9, 18.8. HRMS (FAB+): m/z calc for C36H39N5O7NaS [M+Na+]: 708.2462; found: 708.2495.

4.1.8. 5′-O-(4,4′-Dimethoxytrityl)-2′-O-methyl-N2-isobutyryl-3′-thio- guanosine-3′-S-(2-cyanoethyl)-N,N-Diisopropylphoramidothioite (10)

To a solution of compound 9 (52 mg, 0.076 mmol) in dry dichloromethane (5 mL) under Ar, were added N,N-diisopropylethylamine (66 μL, 0.34 mmol), 2-cyanoethyl N,N-diisopropylchlorophosphoramidite (51μL, 0.34 mmol), and 1-methylimidazole (6.2 μL, 0.076 mmol). The reaction mixture was stirred at room temperature until all the starting material was consumed (1 h). The reaction mixture was quenched with methanol (1 mL), and stirred for 5 min. After the solvent was removed, the residue was purified by silica gel chromatography, eluting with 2% acetone in dichloromethane with 0.5% Et3N to give the corresponding phosphoramidite 10 (100% conversion). 31P NMR (CD3CN): δ 167.0, 161.2. MS (FAB+): m/z calc for C45H57N7O8PS [M+H+]: 886.4; found: 886.2.

4.1.9 Oligonucleotide Synthesis

The oligonucleotide CUCG3′S,2′OCH3A was synthesized on an Expedite 8900 DNA synthesizer through a modified protocol that was previously reported from our laboratory.43 Following standard oligonucleotide deprotection conditions (3:1 NH4OH/EtOH, 4 h; TEA•3HF/NMP, 1.5 h), the MALDI mass spectrum of CUCG3′S,2′OCH3A gave the expected peak at 1557 Da, consistent with the calculated molecular weight (1556 Da).

4.2. Ribozyme reactions

Ribozyme was prepared through standard methods.42 CUCG2′OHA and CUCG2′OCH3A were purchased from Dharmacon (Lafayette, CO) and deprotected according to the manufacturer′s protocol. CUCG3′S,2′OHA was prepared by published procedures.43 All oligonucleotide substrates were 5′-32P-radiolabeled using [γ-32P]ATP (Perkin-Elmer) and T4 polynucleotide kinase (New England Biolabs) according to the manufacturer′s protocols and subsequently purified on a 20% nondenaturing polyacrylamide gel. The band corresponding to the full-length substrate was visualized by autoradiography, excised, and eluted at 4 °C overnight into water. Following elution, the substrate was P/C/I extracted and subsequently ethanol precipitated. Reverse reactions were performed and analyzed essentially as described previously.17 All ribozyme reactions were performed at 30 °C in 50 mM NaEPPS buffer, pH 8.0, 50 mM MgCl2, 1 μM E, and 2 μM P. To stimulate cleavage of the phosphorothiolate substrates, all reactions were performed in the presence of 10 mM MnCl2. To ensure that chemistry was rate-limiting, reactions with CUCG2′OHA and CUCG3′S,2′OHA were performed with -1d,rP (CCCUCdT), a product analogue with a 2'-deoxthymidine at the 3'-terminus. This substitution slows the chemical step while having no effect on other reaction steps.44 For the corresponding 2′-methoxy analogues, no reaction was observed with -1d,rP. Therefore, reactions were performed in the presence of an all-ribo product (CCCUCU) and the resulting kobs was divided by 1188, the reported differential in reactivity between rP and -1d,rP.44 Each rate constant represents the average of two independent determinations that vary by less than 25%.

Acknowledgments

J.L. is a Research Associate, N.-S.L. is a Research Specialist, R.N.S. is a Research Technician, and J.A.P. is an Investigator of the Howard Hughes Medical Institute. We thank Q. Dai for assistance with MALDI mass spectrometry and C. Lea for assistance with substrate preparation and kinetic measurements. We thank J. Ye, T. Novak, J. Min De-Bartolo, S. Koo and Q. Dai for helpful discussions and critical comments on the manuscript.

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errorsmaybe discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

*

The preparation of 3′-thioguanosine was previously described.34,43 The syntheses of 2′-amino-3′-thioguanosine and 2′-methylamino 3′-thioguanosine have yet to be published.

References and notes

  • 1.Curley JF, Joyce CM, Piccirilli JA. J. Am. Chem. Soc. 1997;119:12691–12692. [Google Scholar]
  • 2.Gordon PM, Piccirilli JA. Nat. Struct. Biol. 2001;8:893–898. doi: 10.1038/nsb1001-893. [DOI] [PubMed] [Google Scholar]
  • 3.Piccirilli JA, Vyle JS, Caruthers MH, Cech TR. Nature. 1993;361:85–88. doi: 10.1038/361085a0. [DOI] [PubMed] [Google Scholar]
  • 4.Shah R, Cosstick R, West SC. Embo J. 1997;16:1464–1472. doi: 10.1093/emboj/16.6.1464. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Sontheimer EJ, Sun S, Piccirilli JA. Nature. 1997;388:801–805. doi: 10.1038/42068. [DOI] [PubMed] [Google Scholar]
  • 6.Warnecke JM, Sontheimer EJ, Piccirilli JA, Hartmann RK. Nucleic Acids Res. 2000;28:720–727. doi: 10.1093/nar/28.3.720. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Weinstein LB, Jones BC, Cosstick R, Cech TR. Nature. 1997;388:805–808. doi: 10.1038/42076. [DOI] [PubMed] [Google Scholar]
  • 8.Gordon PM, Sontheimer EJ, Piccirilli JA. RNA. 2000;6:199–205. doi: 10.1017/s1355838200992069. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Brautigam CA, Sun S, Piccirilli JA, Steitz TA. Biochemistry. 1999;38:696–704. doi: 10.1021/bi981537g. [DOI] [PubMed] [Google Scholar]
  • 10.Horton NC, Connolly BA, Perona JJ. J. Am. Chem. Soc. 2000;122:3314–3324. [Google Scholar]
  • 11.Vyle JS, Connolly BA, Kemp D, Cosstick R. Biochemistry. 1992;31:3012–3018. doi: 10.1021/bi00126a024. [DOI] [PubMed] [Google Scholar]
  • 12.Beevers AP, Fettes KJ, O'Neil IA, Roberts SM, Arnold JR, Cosstick R, Fisher J. Chem. Commun. 2002:1458–1459. doi: 10.1039/b203582k. [DOI] [PubMed] [Google Scholar]
  • 13.Beevers APG, Witch EM, Jones BCNM, Cosstick R, Arnold JRP, Fisher J. Magnetic Resonance in Chemistry. 1999;37:814–820. [Google Scholar]
  • 14.Elliott SL, Brazier J, Cosstick R, Connolly BA. J. Mol. Biol. 2005;353:692–703. doi: 10.1016/j.jmb.2005.08.048. [DOI] [PubMed] [Google Scholar]
  • 15.Szczelkun MD, Connolly BA. Biochemistry. 1995;34:10724–10733. doi: 10.1021/bi00034a004. [DOI] [PubMed] [Google Scholar]
  • 16.Gordon PM, Fong R, Piccirilli JA. Chem. Biol. 2007;14:607–612. doi: 10.1016/j.chembiol.2007.05.008. [DOI] [PubMed] [Google Scholar]
  • 17.Hougland JL, Kravchuk AV, Herschlag D, Piccirilli JA. PLoS Biol. 2005;3:e277. doi: 10.1371/journal.pbio.0030277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Shan S, Yoshida A, Sun S, Piccirilli JA, Herschlag D. Proc. Natl. Acad. Sci. U. S. A. 1999;96:12299–12304. doi: 10.1073/pnas.96.22.12299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Sontheimer EJ, Gordon PM, Piccirilli JA. Genes Dev. 1999;13:1729–1741. doi: 10.1101/gad.13.13.1729. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Szewczak AA, Kosek AB, Piccirilli JA, Strobel SA. Biochemistry. 2002;41:2516–2525. doi: 10.1021/bi011973u. [DOI] [PubMed] [Google Scholar]
  • 21.Yoshida A, Sun S, Piccirilli JA. Nat. Struct. Biol. 1999;6:318–321. doi: 10.1038/7551. [DOI] [PubMed] [Google Scholar]
  • 22.Hougland JL, P. J, Forconi M, Lee J, Herschlag D. In: The RNA World. 3rd ed. Gesteland RF, C. T, Atkins JF, editors. Cold Spring Harbor Laboratory Press; Cold Spring Harbor, New York: 2006. pp. 133–205. [Google Scholar]
  • 23.Stahley MR, Strobel SA. Curr. Opin. Struct. Biol. 2006;16:319–326. doi: 10.1016/j.sbi.2006.04.005. [DOI] [PubMed] [Google Scholar]
  • 24.Vicens Q, Cech TR. Trends Biochem. Sci. 2006;31:41–51. doi: 10.1016/j.tibs.2005.11.008. [DOI] [PubMed] [Google Scholar]
  • 25.Das SR, Fong R, Piccirilli JA. Curr. Opin. Chem. Biology. 2005;9:585–593. doi: 10.1016/j.cbpa.2005.10.009. [DOI] [PubMed] [Google Scholar]
  • 26.Gordon PM, Fong R, Deb SK, Li NS, Schwans JP, Ye JD, Piccirilli JA. Chem. Biol. 2004;11:237–246. doi: 10.1016/j.chembiol.2004.02.011. [DOI] [PubMed] [Google Scholar]
  • 27.Hougland JL, Deb SK, Maric D, Piccirilli JA. J. Am. Chem. Soc. 2004;126:13578–13579. doi: 10.1021/ja0469129. [DOI] [PubMed] [Google Scholar]; (b) Hougland JL, Sengupta RN, Dai, Deb QS, Piccirilli JA. manuscript in preparation.
  • 28.Abboud JLM, Roussel C, Gentric E, Sraidi K, Lauransan J, Guiheneuf G, Kamlet MJ, Taft RW. J. Org. Chem. 1988;53:1545–1550. [Google Scholar]
  • 29.Allen FH, Bird CM, Rowland RS, Raithby PR. Acta Crystallographica Section B-Structural Science. 1997;53:696–701. [Google Scholar]
  • 30.Crampton MR. Acidity and hydrogen bonding. John Wiley & Sons; New York: 1974. [Google Scholar]
  • 31.Meotner M, Sieck LW. J. Am. Chem. Soc. 1986;108:7525–7529. doi: 10.1021/ja00284a014. [DOI] [PubMed] [Google Scholar]
  • 32.Platts JA, Howard ST, Bracke BRF. J. Am. Chem. Soc. 1996;118:2726–2733. [Google Scholar]
  • 33.Yoshida A, Shan S, Herschlag D, Piccirilli JA. Chem. Biol. 2000;7:85–96. doi: 10.1016/s1074-5521(00)00074-0. [DOI] [PubMed] [Google Scholar]
  • 34.Matulic-Adamic J, Beigelman L. Helv. Chim. Acta. 1999;82:2141–2150. [Google Scholar]
  • 35.Ozols AM, Azhayev AV, Dyatkina NB, Krayevsky AA. Synthesis. 1980:557–559. [Google Scholar]
  • 36.Ellervik U, Magnusson G. Tetrahedron Lett. 1997;38:1627–1628. [Google Scholar]
  • 37.Bevilacqua PC, Sugimoto N, Turner DH. Biochemistry. 1996;35:648–658. doi: 10.1021/bi951962z. [DOI] [PubMed] [Google Scholar]
  • 38.Karbstein K, Carroll KS, Herschlag D. Biochemistry. 2002;41:11171–11183. doi: 10.1021/bi0202631. [DOI] [PubMed] [Google Scholar]
  • 39.Mei R, Herschlag D. Biochemistry. 1996;35:5796–5809. doi: 10.1021/bi9527653. [DOI] [PubMed] [Google Scholar]
  • 40.Woodson SA, Cech TR. Cell. 1989;57:335–345. doi: 10.1016/0092-8674(89)90971-9. [DOI] [PubMed] [Google Scholar]
  • 41.Zaug AJ, Cech TR. Science. 1986;231:470–475. doi: 10.1126/science.3941911. [DOI] [PubMed] [Google Scholar]
  • 42.Zaug AJ, Grosshans CA, Cech TR. Biochemistry. 1988;27:8924–8931. doi: 10.1021/bi00425a008. [DOI] [PubMed] [Google Scholar]
  • 43.Sun S, Yoshida A, Piccirilli JA. RNA. 1997;3:1352–1363. [PMC free article] [PubMed] [Google Scholar]
  • 44.McConnell TS. Ph.D. thesis. University of Colorado; Boulder, CO: 1995. [Google Scholar]

RESOURCES